Silver Has Hit The Target And Marked A New One!

Posted on by Aibek Burabayev

Aibek Burabayev - INO.com Contributor - Metals


Silver has overshot the target set at the $20 mark in my June post leaving the gold in the dust. The AB/CD concept is simple yet effective as it utilizes perpetual Fibonacci ratios.

Ok, that’s done, but what is next? Let’s look at the charts below. I put the monthly chart first to refresh the global outlook for the soaring metal.

Chart 1. Silver Monthly: The Game Just Started!

Monthly Chart of Silver
Chart courtesy of tradingview.com

The metal has finally shot above the black downtrend, which I was talking about in my March update. It was a vital need for silver to break loose from the multi-year grip to stop the drop. Continue reading "Silver Has Hit The Target And Marked A New One!" →

Can Cheap Money Continue To Drive The Market?

Posted on by The INO.com Team

Hello MarketClub members everywhere. Once again it falls on the shoulders of the Federal Reserve to keep monetary policy loose. With expectations of 4 rate hikes in 2016, we are down to one at this moment in time. I doubt that the Fed has it in them to raise rates again in 2016, which means that 2017 is going to be a reset year for America. Not only are we going to see a new president, but the likely hood is we are going to see a reset of interest rate here in the US.

MarketClub's Mid-day Market Report

Last week, the surprise was the non-farm payroll figure showing 287,000 jobs created compared to 175,000 forecast. Look for this number to be revised downward in the future. The non-farm payroll figure was enough to jump start the equity markets pushing the S&P 500 (CME:SP500) to close within a point lower than its best ever close on May 21st, 2015 at 2,130.82. The DOW (INDEX:DJI) followed but was unable to overcome its highs at 18,351.36 on May 20th, 2015. Both of these indices are now in a positive mode according to the Trade Triangles. The only laggard in the group is the NASDAQ (NASDAQ:COMP) index which has moved into a neutral mode requiring a sideline position. Continue reading "Can Cheap Money Continue To Drive The Market?" →

How To Profit From Brexit - Guaranteed!

Posted on by George Yacik

George Yacik - INO.com Contributor - Fed & Interest Rates


With interest rates plunging all over the world, including right here in the U.S., many fixed-income investors are scratching their heads about where they can find something that pays more than 1% without taking on a pile of risk.

The answer is right under their noses. Plus, the return is way better than you can get on stocks and bonds (even gold!). Not only that, but the return is guaranteed.

What is this magic investment? Continue reading "How To Profit From Brexit - Guaranteed!" →

5 Reasons To Like This Stock

Posted on by The INO.com Team

Hello MarketClub members everywhere. We have come to the end of the week and it has been a welcome relief to see a little less volatility in the marketplace.

MarketClub's Mid-day Market Report

Looking through my Trade Triangles alerts last night, I noticed this one stock that has many of the winning characteristics I like to see in an individual stock. Let's go through them one by one: Continue reading "5 Reasons To Like This Stock" →

IBB: Brexit Collateral Damage Provides Brief Buying Opportunity

Posted on by Noah Kiedrowski

Noah Kiedrowski - INO.com Contributor - Biotech


As Brexit wreaked havoc on international financial markets, it presented a brief opportunity to capitalize on the collateral damage fallout within the biotechnology cohort. This event may continue to offer entry points as the reverberations are felt throughout the markets. I didn’t factor in the possibility that a major economic power within the EU would vote to relinquish its membership and move forward as an independent nation. However as Brexit became reality, I utilized this opportunity to deploy capital in the biotechnology cohort via the iShares Biotechnology Index ETF (NASDAQ:IBB) as a long-term investor within the space. As the UK proceeded with its divorce from the EU, markets sold off in a meaningful way. Brexit introduced instability throughout the region thus negatively impacting financial markets abroad. I largely view the Brexit as an extraneous event unrelated directly to the biotechnology cohort; thus I utilized this brief opportunity to add to my position in IBB and may continue to add in periods of weakness. Continue reading "IBB: Brexit Collateral Damage Provides Brief Buying Opportunity" →